HOME >> MEDICINE >> NEWS
Novartis announces collaboration with Bayer for EMSELEX

Basel, 17 December 2004 Novartis Pharma AG announced today the start of a collaboration between Novartis Pharma GmbH and Bayer Vital AG for the commercialization and distribution of EMSELEX (darifenacin hydrobromide), 7.5 mg and 15 mg in Germany. The collaboration is effective following an agreement between Bayer Vital AG and Novartis Pharma GmbH. EMSELEX, a new once-daily M3 selective receptive antagonist (M3 SRA) recently received Marketing Authorization from the European Commission in 25 European member states, plus Norway and Iceland for the treatment of overactive bladder (OAB).

"Bayer Vital has significant expertise of the German urology market, so collaborating with them helps to ensure that EMSELEX will reach physicians quickly and ultimately benefit patients who suffer from overactive bladder," said Kurt Graves, Chief Marketing Officer, Novartis Pharma AG. "EMSELEX is a new effective drug for the treatment of OAB that is selective for the M3 receptors in the bladder, with proven efficacy, good tolerability and with a well established central nervous system and cardiovascular safety profile." Under the terms of the collaboration, Novartis remains the owner of the marketing authorization for darifenacin, while Bayer Vital gains exclusive commercialization rights for EMSELEX in Germany.

About EMSELEX
EMSELEX is a once-daily M3 selective receptive antagonist (M3 SRA) oral treatment that works by selectively inhibiting the M3 receptor, the primary mediator of detrusor contraction, whilst sparing the M1 and M2 receptors that are located in various body organs, including the brain and heart. EMSELEX has been shown to effectively reduce the number of weekly incontinence episodes by up to 77% versus placebo.1 Additional clinical trials comparing EMSELEX with placebo showed that EMSELEX does not impair cognitive function and has a cardiovascular safety profile similar to placebo.

To date, 98 clinical trials with EMSELEX ha
'"/>

Contact: Eric Althoff
eric.althoff@pharma.novartis.com
41-61-324-6392
Ketchum
17-Dec-2004


Page: 1 2 3

Related medicine news :

1. Dr. Judah Folkman honored with American Heart Association/Novartis award
2. Drs. Gerald DiBona and John Hall receive American Heart Association/Novartis award
3. Novartis receives FDA approval for Starlix, a new treatment for type 2 diabetes
4. Novartis receives FDA approval for LESCOL XL 80 mg
5. The Gerontological Society of America announces Hartford Fellowship recipients
6. TB Alliance announces new drug discovery program with GlaxoSmithKline
7. ASGE announces grant recipients in annual research awards program
8. American College of Chest Physicians announces new Critical Care Institute
9. Eyetech Pharmaceuticals, Inc. announces macugen data on treating macular degeneration
10. Department of Energy announces new agreement with USC, national labs and private company
11. ACP announces international medical fellowship

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/26/2020)... ... February 26, 2020 , ... ... is celebrating Rare Disease Week 2020 by making the comprehensive genomic landscape of ... this data set will provide genetic insight for doctors and researchers searching for ...
(Date:2/26/2020)... ... February 26, 2020 , ... Nutricare’s PATCH bamboo bandages ... be showcasing their pioneering line of compostable bamboo bandages while competing for one of ... West, and we were blown away by the support and interest in green healthcare ...
(Date:2/21/2020)... ... February 21, 2020 , ... Dr. Stong, a leading Atlanta ... back. He has been a long-time volunteer with Healing the Children (HTC) , ... HTC trip is to provide cleft lip and palate procedures to underprivileged pediatric patients ...
(Date:2/21/2020)... ... 2020 , ... Cosmetic surgery continues to grow in popularity ... (ASPS). According to the ASPS, there were 17.7-million cosmetic procedures performed in the ... The American Society of Plastic Surgeons reported that some of the most popular ...
(Date:2/20/2020)... ... 2020 , ... R3 Stem Cell, the nation's leader in regenerative therapies and ... stem cell procedures on military veterans in 2019. The veterans traveled from all ... R3 Stem Cell Training Course for doctors , providers of all kinds learn how ...
Breaking Medicine News(10 mins):
(Date:2/21/2020)... ... February 21, 2020 , ... The business of healthcare management ... up with industry trends and ensuring patients digital and physical safety, there are many ... , That’s why MaintenX International’s is excited to provide their insights on healthcare ...
(Date:2/20/2020)... ... February 20, 2020 , ... Amada Senior Care of Long ... care from trained and knowledgeable Amada caregivers. From day one of opening, owners ... client’s unique needs, preferences and desires, all with the goal of delivering the ...
(Date:2/20/2020)... (PRWEB) , ... February 20, 2020 , ... ... on addressing unmet needs in the field of urology, today announced that Jayant ... Center of Excellence. The designation recognizes that Dr. Uberoi has achieved a high ...
Breaking Medicine Technology:
Cached News: